Skip to main content
NewslettersWatchlist

Abbvie Inc(ABBV-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303

Newswire.ca - Tue Mar 5, 6:00AM CST

This is the eighth drug using Dragonfly's platform technology, and the sixth TriNKET® to enter into clinical trials.

WALTHAM, Mass., March 5, 2024 /CNW/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced receipt of a milestone payment following dosing of the first patient in a clinical trial conducted by AbbVie (NYSE: ABBV) to evaluate ABBV-303, a solid tumor targeting TriNKET®.

Read more at newswire.ca

Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

market news
At midday: TSX rises after inflation slides to 3-year low
The Art Deco facade of the original Toronto Stock Exchange building is seen on Bay Street in Toronto in January of 2019.
inside the market
Before the Bell: What every Canadian investor needs to know today
Traders work on the floor of the New York Stock Exchange during morning trading on May 17, 2024 in New York City. Wall Street stocks opened little changed May 17 after pulling back from a record run where the Dow exceeded 40,000 points for the first time. Around 10 minutes into trading the Dow Jones Industrial Average was steady at 39,872.66. (Photo by ANGELA WEISS / AFP) (Photo by ANGELA WEISS/AFP via Getty Images)
report on business
ReconAfrica agrees to pay out more than $10-million over allegedly misleading disclosure
ReconAfrica oil drilling site in Namibia for Geoffrey York and Emma Graney story.
inside the market
Dividend investing has lost its mojo. Here’s why – and how to adapt
Ian McGugan
inside the market
The Globe Investing Club 2024: Let the competition begin!
opinion
Here’s the real reason your Canadian stocks can’t keep up
Tim Shufelt
market news
Dow ends above 40,000 milestone, TSX also at fresh record high
Traders work on the floor of the New York Stock Exchange (NYSE) on May 16.
number cruncher
U.S technology stocks with earnings and price momentum
For Number Cruncher column in Globe Investor/ROB only.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).